In KRAS-mutant adenocarcinoma, the median OS was 20.9 months in Q1 compared to 20.2 months in Q4 (HR 0.99, 95% CI: 0.91–1.08, p = 0.75) (Supplemental Figure S2B). Here, KRAS is linked to adenocarcinoma.